Welcome to our dedicated page for Vanda Pharma SEC filings (Ticker: VNDA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Vanda Pharmaceuticals Inc. (VNDA) SEC filings page on Stock Titan provides access to the company’s official regulatory documents as filed with the U.S. Securities and Exchange Commission. These filings offer detailed insight into how Vanda describes its commercial portfolio, clinical pipeline, financial condition, and interactions with the U.S. Food and Drug Administration.
Recent Form 8-K filings referenced by Vanda include earnings announcements and disclosures about a collaborative framework with the FDA regarding HETLIOZ (tasimelteon) and tradipitant. Through these current reports, investors can review management’s discussion of net product sales for Fanapt, HETLIOZ, and PONVORY, as well as updates on NDAs and BLAs for programs such as Bysanti, tradipitant in motion sickness, and imsidolimab in generalized pustular psoriasis.
On Stock Titan, VNDA filings are updated in near real time from EDGAR and paired with AI-powered summaries that explain the key points of lengthy documents. For annual reports on Form 10-K and quarterly reports on Form 10-Q, AI highlights sections related to Vanda’s commercial products, research and development spending, and risk factors tied to regulatory decisions and clinical trial outcomes. For current reports on Form 8-K, AI summaries focus on the specific material events being disclosed, such as financial results or significant regulatory agreements.
Users can also review other SEC forms associated with VNDA, including exhibits attached to 8-K filings that contain press releases or detailed descriptions of regulatory milestones. For investors analyzing Vanda’s work in sleep-wake disorders, psychiatric conditions, motion sickness, and rare inflammatory skin disease, these filings provide a structured view of the company’s obligations, forward-looking statements, and disclosed risks, while the AI tools on Stock Titan help make the technical language more accessible.
Vanda Pharmaceuticals Inc. reported Q1 2026 revenue of $51.7 million, up slightly from $50.0 million a year earlier, driven mainly by stronger Fanapt and PONVORY sales. Net loss widened to $48.6 million from $29.5 million as selling, general and administrative expenses rose to $68.4 million and research and development remained high at $28.4 million.
Cash and cash equivalents were $54.0 million with a further $148.3 million in marketable securities, and management believes this liquidity plus product sales can fund operations for at least 12 months. HETLIOZ sales declined amid U.S. generic competition, while Fanapt prescriptions grew strongly. The company highlighted FDA approval of milsaperidone for bipolar I disorder and schizophrenia, U.S. launch of NEREUS for motion-induced vomiting, and acceptance of a BLA for imsidolimab in generalized pustular psoriasis with a PDUFA date of December 12, 2026.
Vanda Pharmaceuticals reported Q1 2026 net product sales of $51.7 million, a 3% increase from Q1 2025, driven by 26% Fanapt® sales growth to $29.6 million. HETLIOZ® sales fell to $15.9 million, while PONVORY® rose to $6.2 million.
The company posted a net loss of $48.6 million (diluted loss per share $0.82), wider than the prior-year loss, reflecting higher selling, general and administrative spending and investments in launches and pipeline programs. Cash, cash equivalents and marketable securities totaled $202.3 million as of March 31, 2026.
Vanda raised its full-year 2026 revenue guidance to $240–$290 million, including $10–$30 million expected from newly launched NEREUS™. The quarter also featured FDA approval of BYSANTI™ (milsaperidone) for bipolar I disorder and schizophrenia and FDA acceptance of a BLA for imsidolimab in Generalized Pustular Psoriasis with a PDUFA target action date of December 12, 2026.
BlackRock Portfolio Management LLC filed an amendment to a Schedule 13G/A reporting beneficial ownership of 2,508,488 shares of Vanda Pharmaceuticals Inc. Common Stock. The filing shows 2,206,827 shares with sole voting power and states this equals 4.2% of the class.
Vanda Pharmaceuticals director Duncan Charles Cliff received an equity award of 57,101 shares of common stock in the form of restricted stock units (RSUs). The grant carries no cash exercise price and is recorded as a direct ownership position.
The RSU award is time-based and will vest in four equal annual installments, with the first vesting date on April 22, 2027, provided Cliff continues to serve the company through each annual vesting date. After this grant, his reported direct holdings from this award total 57,101 shares.
Vanda Pharmaceuticals Inc. director Duncan Charles Cliff filed an initial statement of beneficial ownership on Form 3. This filing identifies him as a director of Vanda and provides a baseline disclosure of his equity position and reporting status, without showing any reportable transactions in the provided data.
Vanda Pharmaceuticals is asking stockholders to vote at its virtual 2026 annual meeting on June 4, 2026. Proposals include electing three Class II directors through 2029, ratifying PricewaterhouseCoopers as auditor, an advisory vote on executive pay and increasing shares under the 2016 Equity Incentive Plan.
The record date is April 17, 2026, with 60,135,062 common shares outstanding. The proxy highlights 2025 total revenue of $216.1 million, including Fanapt, HETLIOZ and PONVORY sales, year-end cash and securities of $263.8 million and a net loss of $220.5 million after a large non-cash tax valuation allowance. It also outlines multiple late-stage clinical programs, an FDA approval for tradipitant in motion sickness and a BLA filing for imsidolimab in generalized pustular psoriasis.
Vanda Pharmaceuticals Inc. expanded its Board of Directors from six to seven members and appointed Charles C. Duncan, Ph.D., as a Class II director, with his initial term running until the company’s 2026 annual stockholders’ meeting. Under Vanda’s outside director compensation program, Dr. Duncan received an initial restricted stock unit award with a grant date value of $390,000 as of April 22, 2026, vesting in four equal annual installments while he serves on the board, and he will receive a $50,000 annual cash fee paid quarterly. Beginning with the 2026 annual meeting, he will be eligible for additional annual restricted stock unit awards with a grant date value of $260,000, vesting one year from grant, with all such awards becoming fully vested upon a change of control. Vanda states that Dr. Duncan is an independent director and has entered into its standard Delaware law indemnification agreement for directors.
Vanda Pharmaceuticals Inc. executive Christos Vasilios Mihael Polymeropoulos, Senior VP and Medical Director, filed an initial ownership report showing his equity positions in the company. He holds a stock option to buy 61,200 shares of common stock at an exercise price of $7.05 per share, expiring on February 15, 2033. The filing also lists multiple common stock and restricted stock unit (RSU) awards, with time-based vesting schedules running from March 1, 2027 through March 1, 2029, contingent on his continued employment and delivery of vested shares on the first permissible trading day after each vest date.